Autopsy report · NCT00122629
Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders
Cause of deathNo reason given
Life of this trial
- Registered 4 years 9 months after it had already started.
- Ran for about 2 years 7 months before it stopped.
- 405 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Sponsor type
- Government (non-US federal)
- Conditions
- Hepatitis C, Chronic
- Interventions
- peg-interferon alfa-2b; ribavirin; amantadine
- Participants
- 405
- Sites
- 1
- Countries
- France
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.